Safety of biologics in inflammatory bowel disease

Current Treatment Options in Gastroenterology

Volumn 9, Issue 3, 2006, Pages 221-233

  Blonski, Wojciech ^b   Lichtenstein, Gary R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DIPHENHYDRAMINE; DRUG ANTIBODY; ETANERCEPT; GAMMA INTERFERON ANTIBODY; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIVER ENZYME; MLN 02; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH5D12; NATALIZUMAB; ONERCEPT; PARACETAMOL; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SEMAPIMOD; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL ABSCESS; ABSCESS; ANOREXIA; ARTHRALGIA; BACKACHE; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BLOOD CLOTTING DISORDER; CELLULITIS; CHILL; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EDEMA; ENTERITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALING; HUMAN; INFECTION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE REACTION; LIVER DYSFUNCTION; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOMA; MAINTENANCE THERAPY; MIGRAINE; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEUTROPHILIA; OPTIC NEURITIS; PARTIAL THROMBOPLASTIN TIME; PHLEBITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; REMISSION; REVIEW; RIGOR; SEPSIS; SKIN MANIFESTATION; SKIN ULCER; THORAX PAIN; THROMBOCYTOPENIA; TUBERCULOSIS; ULCERATIVE COLITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRAL GASTROENTERITIS; VIRUS INFECTION; VOMITING;

EID: 33744954599     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0041-4     Document Type: Review

References (70)

1. Sandborn WJ, Faubion WA: Biologics in inflammatory bowel disease: How much progress have we made? Gut 2004, 53:1366-1373.
2. Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122:1592-1608.
3. Brown S, Abreu M: Biologic therapies in inflammatory bowel disease. Practical Gastroenterology 2005, XXIX:38-63.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
5. Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000, 119:1148-1157.
6. Remicade® [package insert]. Horsham, PA: Centocor; 2005.
7. Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
8. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
10. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
11. Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002, 97:2962-2972.
12. Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728-1733.
13. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
14. Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
15. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000, 49:1-51.
16. Lewis JD, Bilker WB, Brensinger C, et al.: Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
17. Ekbom A, Helmick C, Zack M, Adami HO: Extracolonic malignancies in inflammatory bowel disease. Cancer 1991, 67:2015-2019.
18. Karlen P, Lofberg R, Brostrom O, et al.: Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999, 94:1047-1052.
19. Persson PG, Karlen P, Bernell O, et al.: Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675-1679.
20. Loftus EV, Jr, Tremaine WJ, Habermann TM, et al.: Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000, 95:2308-2312.
21. Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
22. Palli D, Trallori G, Bagnoli S, et al.: Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000, 119:647-653.
23. Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
24. Rutgeerts P, D'Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
25. Colombel JF, Loftus EV, Jr, Tremaine WJ, et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004, 126:19-31.
26. Katz JA, Antoni C, Keenan GF, et al.: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
27. Lichtenstein GR, Cohen R, Feagan B, et al.: Safety of infliximab and other Crohn's disease therapies - updated TREAT registry data with over 10,000 patients-years of follow-up [abstract]. Gastroenterology 2005, 128:W1034.
28. Stack WA, Mann SD, Roy AL, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997, 349:521-524.
29. Feagan B, Sandborn W, Baker J, et al.: A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease [abstract]. Gastroenterology 2000, 118:A655.
30. Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001, 120:1330-1338.
31. Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004, 53:1485-1493.
32. Evans RC, Clarke L, Heath P, et al.: Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997, 11:1031-1035.
33. Rutgeerts P, Lemmens L, Van Assche G, et al.: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17:185-192.
34. Enbrel® [package insert]. Collegeville, PA: Wyeth Pharmaceuticals; 2005.
35. D'Haens G, Swijsen C, Noman M, et al.: Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001, 96:2564-2568.
36. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
37. Hommes D, van den Blink B, Plasse T, et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122:7-14.
38. Winter TA, Wright J, Ghosh S, et al.: Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004, 20:1337-1346.
39. Schreiber S, Rutgeerts P, Fedorak R, et al.: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) in active Crohn's disease. Gastroenterology 2005, 129:807-818.
40. Sandborn W, Hanauer S, Lucas M, et al.: Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-alpha monoclonal antibody adalimumab (humira) [abstract]. Gastroenterology 2005, 128:A112-A113.
41. Hanauer S, Lukas M, Macintosh D, et al.: A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease [abstract]. Gastroenterology 2004, 127:332.
42. Sandborn W, Hanauer S, Loftus E, Jr, et al.: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease [abstract]. Gastroenterology 2004, 126:A53-A54.
43. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998, 114:1133-1142.
44. Schreiber S, Nikolaus S, Malchow H, et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001, 120:1339-1346.
45. Yacyshyn BR, Chey WY, Goff J, et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002, 51:30-36.
46. Yacyshyn BR, Barish C, Goff J, et al.: Dose ranging pharmacokinetic trial of high-dose alicaforsen (inter-cellular adhesion molecule-1 antisense oligodeoxy-nucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002, 16:1761-1770.
47. Chey WY, Konecny M, Rydzewska G, et al.: Two phase 3 studies of Alicaforsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease [abstract]. Gastroenterology 2005, 128:A112.
48. Van Deventer S, Volfova M, Flisiak R, et al.: A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left sided ulcerative colitis [abstract]. Gastroenterology 2005, 128:A74.
49. Miner P, Nichols T, Schwartz H, et al.: A phase 2 trial to assess the safety and efficacy of two dose formulations of alicaforsen enema compared with 4g mesalamine enema for acute ulcerative colitis [abstract]. Gastroenterology 2005, 128:A74.
50. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D 2004, 5:102-107.
51. Gordon FH, Lai CW, Hamilton MI, et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001, 121:268-274.
52. Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
53. Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005, 353:1912-1925.
54. Sands B, Kozarek R, Spainhour J, et al.: Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease [abstract]. Gastroenterology 2004, 126:A463.
55. Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699-705.
56. Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
57. Langer-Gould A, Atlas SW, Green AJ, et al.: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
58. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
59. Adelman B, Sandrock A, Panzara MA: Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005, 353:432-433.
60. Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
61. Inc. MP http://investor.millennium.com/phoenix.zhtml?c=80159&p= irol-newsmediaArtide&ID=333736&highlight= Accessed December 15, 2005.
62. Kasran A, Boon L, Wortel CH, et al.: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005, 22:111-122.
63. Plevy S, Salzberg B, Van Assche G, et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 2004, 126:A75.
64. Rutgeerts P, Van Deventer S, Schreiber S: Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease-focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 2003, 17:1435-1450.
65. van Deventer SJ, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997, 113:383-389.
66. Schreiber S, Fedorak RN, Nielsen OH, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000, 119:1461-1472.
67. Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473-1482.
68. Colombel JF, Rutgeerts P, Malchow H, et al.: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001, 49:42-46.
69. Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999, 117:58-64.
70. Sands BE, Winston BD, Salzberg B, et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002, 16:399-406.